The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 3, 2012, Pages 260-264

  Mnyani, Coceka N ^a   McIntyre, James A ^a,b   Myer, Landon ^b  

^a ANOVA HEALTH INSTITUTE   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antiretroviral therapy; CD4; HIV; point of care testing; pregnancy; South Africa

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; GESTATIONAL AGE; HEALTH SERVICE; HEMODILUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFORMATION SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; PERFORMANCE; PLACENTAL TRANSFER; PREGNANT WOMAN; PRIORITY JOURNAL; RELIABILITY; SOUTH AFRICA;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SOUTH AFRICA; YOUNG ADULT;

EID: 84864300449     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318256b651     Document Type: Article

References (31)

1. McIntyre J. Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries. Curr Opin HIV AIDS. 2010; 5:48-53.
2. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favourable pregnancy outcomes. AIDS. 2011;25:1611-1618.
3. Abrams EJ, Myer L, Rosenfield A, et al. Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. Am J Obstet Gynecol. 2007;197(suppl 3):101-106.
4. Carter RJ, Dugan K, El-Sadr WM, et al. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr. 2010;55:404-410.
5. Zolfo M, De Weggheleire A, Schouten E, et al. Time for "test and treat" in prevention of mother-to-child transmission programs in low-and middle-income countries. J Acquir Immune Defic Syndr. 2010;55:287-289.
6. World Health Organization, UNAIDS, and UNICEF. Global HIV/AIDS Response-Epidemic Update and Health Sector Progress Towards Universal Access. Progress Report 2011. Geneva, Switzerland: 2011; World Health Organization. Available at: http://www.who.int/hiv/pub/progress-report2011/en/index.html. Accessed November 18, 2011.
7. Zachariah R, Reid SD, Chaillet P, et al. Why do we need a point-of-care CD4 test for low-income countries? Trop Med Int Health. 2011;16:37-41.
8. Myer L. Initiating antiretroviral therapy in pregnancy: the importance of timing. J Acquir Immune Defic Syndr. 2011;58:125-126.
9. Boyle DS, Hawkins KR, Steele MS, et al. Emerging technologies for point-of-care CD4 T-lymphocyte counting. Trends Biotechnol. 2011;30: 45-54.
10. Baum LL, Crowe S, Landay AL. Advances in CD4 cell enumeration in resource-poor countries. Curr Opin HIV AIDS. 2007;2:234-240.
11. Diaw PA, Daneau G, Coly AA, et al. Multi-site evaluation of a point-ofcare instrument for CD4+ T cell enumeration using venous and finger prick blood: the PIMATM CD4. J Acquir Immune Defic Syndr. 2011;58:103-111.
12. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr. 2010;55:1-7.
13. Glencross DK, Coetzee LM, Lawrie D, et al. Encouraging point-of-care PIMA CD4 testing performance in a laboratory setting: Johannesburg, South Africa. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-10, 2010, San Francisco, CA. Abstract V-1003.
14. Van Schaïk N, Kranzer K, Myer L, et al. Field validation of the PIMATM analyser in a mobile clinic setting in South Africa. Poster presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011, Boston, MA. Poster V-144.
15. Sukapirom K, Onlamoon N, Thepthai C, et al. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr. 2011;58: 141-147.
16. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011; 378:1572-1579.
17. Larson B, Bistline K, Ndibongo B, et al. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. Paper presented at: 6th IAS Conference; July 17-20, 2011, Rome, Italy. Abstract MOAD0103.
18. Faal M, Naidoo N, Glencross DK, et al. Providing immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immune Defic Syndr. 2011;58:e54-e59.
19. AlereTM Healthcare. PIMATM CD4. Available at: http://pimatest.com/en/ home.html. Accessed February 27, 2012.
20. Glencross D, Scott LE, Jani IV, et al. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. Cytometry. 2002;50:69-77.
21. Glencross DK, Aggett HM, Stevens WS, et al. African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories. Cytometry B Clin Cytom. 2008;74(suppl 1): 569-579.
22. IQAP. Beckman Coulter Hematology IQAP program, 2009. Available at: http://www.beckman.com/customersupport/cu3.asp#iqap. Accessed November 18, 2011.
23. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician. 1983;32:307-317.
24. Pitman EJG. A note on normal correlation. Biometrika. 1939;31: 9-12.
25. Mofenson LM. Protecting the next generation-eliminating perinatal HIV-1 infection. N Engl J Med. 2010;362:2316-2318.
26. UNICEF. South Africa. Statistics, 2010. Available at: http://www.unicef. org/infobycountry/southafrica-statistics.html. Accessed February 28, 2012.
27. Coutsoudis A, England K, Rollins N, et al. Women's morbidity and mortality in the first 2 years after delivery according to HIV status. AIDS. 2010;24:2859-2866.
28. Mulcahy F, Wallace E, Woods S, et al. CD4 counts in pregnancy do not accurately reflect the need for long-term HAART. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 704b.
29. Ekouevi DK, Inwoley A, Tonwe-Gold B, et al. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses. 2007;23:1469-1474.
30. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2010.
31. Jani I, Sitoe N, Quevedo J, et al. Cost comparison of point-of-care and laboratory CD4 testing in resource-limited settings. Paper presented at: 6th IAS Conference, July 17-20, 2011, Rome, Italy. Abstract MOAD0101.